Loading...
OTCM
DTRK
Market cap485kUSD
Jul 09, Last price  
0.38USD
1D
0.00%
Jan 2017
-96.12%
Name

DATATRAK International Inc

Chart & Performance

D1W1MN
No data to show
P/E
0.18
P/S
0.08
EPS
2.08
Div Yield, %
—
Shrs. gr., 5y
19.42%
Rev. gr., 5y
-3.65%
Revenues
6m
+4.37%
2,245,6314,720,9127,052,15811,305,11215,734,74517,690,33610,561,8688,826,0609,716,22510,900,71111,010,7929,959,7048,982,8677,524,0437,447,3567,742,5697,157,0096,381,5435,925,3946,184,265
Net income
3m
P
-7,354,233-6,390,610-1,048,621817,0342,538,347-4,490,410-10,853,503-16,796,605-1,550,026-138,382-1,306,852-2,898,8701,016,793219,696161,575386,799-90,186-249,883-888,5672,657,418
CFO
4m
P
-6,295,191-5,281,984-125,369-63,2031,717,078658,976-4,776,240-5,321,3471,082,872466,0921,011,478-1,389,8411,238,421157,996460,3152,423,419-1,352,141286,219-2,745,2693,718,451

Profile

DATATRAK International, Inc., a technology and services company, provides unified clinical solutions and related services for the clinical trials industry. The company offers DATATRAK ONE Unified Experience, a clinical enterprise solution that allows clinical users and service providers to design, deliver, and manage clinical trials. Its products include UX CTMS 360 for planning and managing trials; UX Trial to streamline design-to-deployment process using a tool; UX EDC & Medical Coding for capturing and delivering data; UX Randomization and Trial Supply Management to randomize patients and automate supply; UX Patient Data Capture; UX Safety; and UX Training to train users and track certificates. The company also provides DATATRAK Clinical Consulting Services, such as training, support, learning center, Software as a Service hosting, standards, and trial design services. It serves contract research organizations, pharma and biotech companies, and clinical trial device companies. DATATRAK International, Inc. was founded in 1991 and is headquartered in Mayfield Heights, Ohio.
URL
https://www.datatrak.com/
IPO date
Jun 11, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,184
4.37%
5,925
-7.15%
Cost of revenue
1,037
2,250
Unusual Expense (Income)
NOPBT
5,147
3,675
NOPBT Margin
83.23%
62.03%
Operating Taxes
56
(3)
Tax Rate
0.00%
NOPAT
5,147
3,675
Net income
2,657
-399.07%
(889)
255.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
7
BB yield
-0.58%
Debt
Debt current
267
750
Long-term debt
Deferred revenue
3,429
948
Other long-term liabilities
732
Net debt
100
(10)
Cash flow
Cash from operating activities
3,718
(2,745)
CAPEX
(333)
(8,507)
Cash from investing activities
(80)
156
Cash from financing activities
(483)
722
FCF
7,351
3,799
Balance
Cash
167
636
Long term investments
123
Excess cash
463
Stockholders' equity
4,090
269
Invested Capital
1,838
3,476
ROIC
193.75%
128.35%
ROCE
280.09%
99.12%
EV
Common stock shares outstanding
5,670
2,814
Price
0.04
-90.00%
0.40
-95.51%
Market cap
227
-79.85%
1,126
-94.77%
EV
327
1,116
EBITDA
5,214
3,489
EV/EBITDA
0.06
0.32
Interest
37
Interest/NOPBT
1.01%